{
    "clinical_study": {
        "@rank": "62116", 
        "acronym": "PEACE1", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "androgen deprivation therapy"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "androgen deprivation therapy + abiraterone acetate + prednisone"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "Arm A + radiotherapy"
            }, 
            {
                "arm_group_label": "Arm D", 
                "arm_group_type": "Experimental", 
                "description": "Arm B + radiotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center phase III study to compare the clinical benefit of androgen\n      deprivation therapy with or without local radiotherapy with or without abiraterone acetate\n      and prednisone in patient with metastatic hormone-na\u00efve prostate cancer."
        }, 
        "brief_title": "A Phase III of ADT +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-na\u00efve Prostate Cancer.", 
        "completion_date": {
            "#text": "October 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer Adenocarcinoma Metastatic", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible patients can be randomize in the trial after his consent form has been signed, and\n      after all inclusion and non-inclusion criteria have been checked.\n\n      The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone),\n      arm C(ADT + radiotherapy) or arm D (ADT + Abiraterone + radiotherapy) in a 1:1:1:1 ratio.\n\n      The randomization will be stratified (by minimization) according to:\n\n        -  enrolment center,\n\n        -  performance status (0 vs. 1-2)\n\n        -  disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of\n           visceral metastases.\n\n      CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological\n      progression) with serum testosterone being at castrated levels (<0.50 ng/mL).\n\n      When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be\n      maintained in all patients. Patients from arm B and D will then stop abiraterone (in\n      selected cases e.g. slow/asymptomatic progressions, the investigator may consider continuing\n      ADT + abirateroneprednisone at CRPC, rather than switching directly to another therapy, for\n      patients included in the abiraterone arms, the use of prednisone at this stage is left to\n      the investigator decision).\n\n      Investigators will be free to manage patients reaching CRPC at their discretion (using for\n      example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc)\n      according to local uses and guidelines. Abiraterone may be used in arm A and C if\n      abiraterone has become the standard treatment for CRPC when this stage is reached."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Histologically or cytologically confirmed adenocarcinoma of the prostate,\n\n          2. Metastatic disease documented by positive bone scan or CTscan or MRI. For patients\n             with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes can\n             be included if they have either:\n\n               -  At least one extra-pelvic lymph node \u2265 2 cm or\n\n               -  extra-pelvic lymph node (s) \u2265 1 cm if the patients also have at least one pelvic\n                  lymph node \u2265 2 cm\n\n          3. Patients with ECOG \u2264 1 (PS 2 due to bone pain accepted),\n\n          4. Life expectancy \u2265 6 months,\n\n          5. Male aged \u2265 18 years old,\n\n          6. Hemoglobin \u2265 10.0 g/dL,\n\n          7. Platelet count \u2265 100,000/\u03bcL,\n\n          8. Serum creatinine < 1.5 x ULN or calculated creatinine clearance \u2265 60 mL/min,\n\n          9. Serum potassium > 3.5 mmol/L,\n\n         10. Serum bilirubin \u2264 1.5 x ULN (except documented Gilbert's disease); AST and ALT \u2264 2.5\n             x ULN (\u2264 5 ULN in case of liver metastases),\n\n         11. Patients might have received a maximum of 3 months of ADT before randomization,\n\n         12. Patients might have received previous radiation therapy directed to bone lesions, as\n             far as it is terminated by the time of randomization,\n\n         13. Patients able to take oral medication,\n\n         14. Patients who have received the information sheet and signed the informed consent\n             form,\n\n         15. Male patients who are receiving the study treatment and have partners of childbearing\n             potential are advised to use a method of birth control with adequate barrier\n             protection (condoms) as determined to be acceptable by the study doctor during the\n             treatment period and for 4 weeks after the last dose of the study treatment.\n\n         16. Patients must be willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests and other study procedures,\n\n         17. Patients with a public or a private health insurance coverage,\n\n        Exclusion Criteria:\n\n          1. Patients with previous local treatment directed to the prostate primary cancer. A\n             previous TURP is allowed,\n\n          2. Prior cytotoxic chemotherapy or biological therapy for the treatment of CRPC,\n\n          3. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg\n             prednisone/prednisolone twice daily,\n\n          4. Active infection or other medical condition for which corticosteroid use would be\n             contraindicated,\n\n          5. Previously treated with ketoconazole for prostate cancer for more than 7 days,\n\n          6. Prior systemic treatment with an azole drug within 4 weeks of randomization,\n\n          7. Uncontrolled hypertension (systolic BP \u2265 160 mmHg or diastolic BP \u2265 95 mmHg),\n\n          8. Patients with a history of hypertension except if blood pressure is controlled by\n             anti-hypertensive treatment,\n\n          9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's\n             disease),\n\n         10. History of pituitary or adrenal dysfunction,\n\n         11. Small cell carcinoma of the prostate,\n\n         12. Clinically known significant heart disease (myocardial infarction, arterial\n             thrombotic events in the past 6 months, severe or unstable angina,NYHA Class II-IV\n             heart disease or cardiac EF < 50% at baseline,\n\n         13. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,\n\n         14. Other malignancy, except non-melanoma skin cancer, with a \u2265 30% probability of\n             recurrence within 24 months,\n\n         15. Known allergies, hypersensitivity or intolerance to the study drugs or excipients,\n\n         16. Administration of an investigational therapeutic within 30 days of M1 D1,\n\n         17. Patients already included in another therapeutic trial involving an experimental\n             drug,\n\n         18. Patients with significantly altered mental status prohibiting the understanding of\n             the study or with psychological, familial, sociological or geographical condition\n             potentially hampering participation,\n\n         19. Individual deprived of liberty or placed under the authority of a tutor."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "916", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957436", 
            "org_study_id": "UC-0160/1105"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm B", 
                    "Arm D"
                ], 
                "description": "abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid", 
                "intervention_name": "abiraterone acetate", 
                "intervention_type": "Drug", 
                "other_name": "Zytiga"
            }, 
            {
                "arm_group_label": [
                    "Arm C", 
                    "Arm D"
                ], 
                "description": "74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)", 
                "intervention_name": "radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C", 
                    "Arm D"
                ], 
                "description": "The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy", 
                "intervention_name": "Androgen Deprivation Therapy", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgens", 
                "Hormones", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate", 
            "cancer", 
            "metastatic hormone-naive", 
            "radiotherapy", 
            "abiraterone acetate"
        ], 
        "lastchanged_date": "September 30, 2013", 
        "number_of_arms": "4", 
        "official_title": "A Prospective Randomised Phase III Study of Androgen Deprivation Therapy With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-na\u00efve Prostate Cancer.", 
        "overall_contact": {
            "email": "b-juzyna@unicancer.fr", 
            "last_name": "Beata JUZYNA"
        }, 
        "overall_official": [
            {
                "affiliation": "Gustave Roussy, Cancer Campus Grand Paris - Paris", 
                "last_name": "Karim FIZAZI, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Bergoni\u00e9 - Bordeaux", 
                "last_name": "Guilhem ROUBAUD, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinique Pasteur, Toulouse", 
                "last_name": "Igor LATORZEFF, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinique Ste Marguerite - Hy\u00e8res", 
                "last_name": "Jean-Fran\u00e7ois BERDAH, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Fran\u00e7ois Baclesse - Caen", 
                "last_name": "Marlon SILVA, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ICO-Centre Ren\u00e9 Gauducheau - St Herblain", 
                "last_name": "St\u00e9phane SUPIOT, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Claudius R\u00e9gaud - Toulouse", 
                "last_name": "Lo\u00efc MOUREY, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHP Saint Gr\u00e9goire - St Gr\u00e9goire", 
                "last_name": "Xavier ARTIGNAN, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre L\u00e9on B\u00e9rard - Lyon", 
                "last_name": "Aude FLECHON, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinique Armoricaine de radiologie - St Brieuc", 
                "last_name": "Patricia BURBAN-PROVOST, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Car\u00e9meau - N\u00eemes", 
                "last_name": "St\u00e9phane DROUPY, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Jean Godinot - Reims", 
                "last_name": "Jean-Christophe EYMARD, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Timone - Marseille", 
                "last_name": "Xavier MURACCIOLE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Paoli Calmettes - Marseille", 
                "last_name": "Gwena\u00eblle GRAVIS, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Azur\u00e9en de Canc\u00e9rologie - Mougins", 
                "last_name": "Philippe RONCHIN, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Curie - Paris", 
                "last_name": "Philippe BEUZEBOC, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital St Louis - Paris", 
                "last_name": "Christophe HENNEQUIN, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHD Vend\u00e9e - La Roche sur Yon", 
                "last_name": "Frank PRIOU, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Antoine Lacassagne - Nice", 
                "last_name": "Jean-Marc FERRERO, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinique Pasteur - Brest", 
                "last_name": "Ali HASBINI, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Eug\u00e8ne Marquis - Rennes", 
                "last_name": "Brigitte LAGUERRE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ICO-Paul Papin - Angers", 
                "last_name": "Sophie ABADIE-LACOURTOISIE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Hospitalier Alpes Leman - Contamine sur Arve", 
                "last_name": "Carol ALLIOT, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SERA - Contamine sur Arve", 
                "last_name": "Abdennacer GHOUL, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHR La source - Orl\u00e9ans", 
                "last_name": "Thierry WACHTER, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hopitaux du Leman - Thonon les Bains", 
                "last_name": "Jean-Luc LANDRY, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de Canc\u00e9rologie  Lucien Neuwirth - St Priest en Jarez", 
                "last_name": "Guy De LAROCHE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Georges-Fran\u00e7ois LECLERC - Dijon", 
                "last_name": "Etienne MARTIN, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU JEAN MINJOZ - Besan\u00e7on", 
                "last_name": "Antoine THIERY-VUILLEMIN, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Limoges - Limoges", 
                "last_name": "Pierre CLAVERE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Henri Mondor - Cr\u00e9teil", 
                "last_name": "Alexandre De La TAILLE, Doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHU Rouen - Rouen", 
                "last_name": "Christian PFISTTER, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall and progression-free survival", 
            "measure": "Survival", 
            "safety_issue": "No", 
            "time_frame": "5.5 years after the first inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957436"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The PSA response rate will be defined by an undetectable serum PSA level at 8 months", 
                "measure": "PSA response rate", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "measure": "Prospective correlative study of PSA response/progression", 
                "safety_issue": "No", 
                "time_frame": "8 months"
            }, 
            {
                "measure": "Prostate cancer specific survival", 
                "safety_issue": "Yes", 
                "time_frame": "5.5 years"
            }, 
            {
                "description": "will be evaluated by questionnaires", 
                "measure": "Time to pain progression", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }, 
            {
                "measure": "Time to next skeletal-related event", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }, 
            {
                "measure": "Time to chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }, 
            {
                "description": "The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effets will be evaluated according to NCI-CTCAE v4.0", 
                "measure": "Time to severe local symptoms", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }, 
            {
                "description": "Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "5.5 years"
            }, 
            {
                "measure": "The radiological progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }, 
            {
                "measure": "Impact of radiotherapy protocol on outcome", 
                "safety_issue": "No", 
                "time_frame": "5.5 years"
            }
        ], 
        "source": "UNICANCER", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen-Cilag Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}